Compounds > n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide
Page last updated: 2024-09-05

n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and Colorectal Neoplasms

n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide has been researched along with Colorectal Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Funahashi, Y; Hamaoka, S; Haneda, T; Kamata, J; Nara, K; Okabe, T; Owa, T; Ozawa, Y; Semba, T; Sugi, NH; Takahashi, K; Tsukahara-Tamai, N; Tsuruoka, A; Ueda, N; Wakabayashi, T; Yamamoto, Y; Yonaga, M; Yoshimatsu, K1

Other Studies

1 other study(ies) available for n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and Colorectal Neoplasms

ArticleYear
Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
    Cancer research, 2002, Nov-01, Volume: 62, Issue:21

    Topics: Angiogenesis Inhibitors; Animals; Cell Division; Colorectal Neoplasms; Endothelium, Vascular; Female; Humans; Indoles; Integrin alpha2; Mice; Mice, Nude; Sulfonamides; Xenograft Model Antitumor Assays

2002